key: cord-1020658-todasxpa
authors: Hirota, Kazuyoshi; Lambert, David G.
title: Propofol and SARS-CoV-2 infection
date: 2020-09-01
journal: Br J Anaesth
DOI: 10.1016/j.bja.2020.08.032
sha: d69858ce947dc2a153eb71b45414c40b2fc3e73e
doc_id: 1020658
cord_uid: todasxpa

nan

concentrations of propofol (50 and 100 µM) in human umbilical vein endothelial cells, Zhang and colleagues [3] found increased expression of ACE2/Ang(1-7)/Mas receptors and phosphorylation of endothelial nitric oxide synthase to inhibit angiotensin 2-induced apoptosis. ACE2 is widely expressed in human cells and tissues and is a target cell receptor for internalization of SARS-CoV-2 [5] . Continuous infusion of propofol has the potential to increase tissue concentrations and then upregulate ACE2. It is therefore possible that propofol could enhance internalization of SARS-CoV-2 to precipitate and exacerbate development and persistence of COVID-19.

On the other hand, propofol may have beneficial effects against SARS-CoV-2. Clinically relevant (total) concentrations of propofol displaced the binding of (+)[ 3 H]SKF-10047 (a selective σ1 receptor agonist) with a propofol K i of 10.2 µM (K i : a 'measure' of binding affinity). Propofol may be a σ1 receptor antagonist [6] . In their repurposing paper, Gordonand colleagues [7] identified two sets of pharmacological agents displaying antiviral activity:

inhibitors of mRNA translation and predicted regulators of σ1 and σ2 receptors. As σ1 and σ2 receptor antagonists suppress SARS-CoV-2, σ1 antagonist effects (by propofol) may provide a beneficial action against COVID-19. In addition, as propofol has both anti-oxidant and anti-inflammatory actions [8] , it may reduce SARS-CoV-2 induced systemic inflammation and thereby provide organ protection.

Propofol is commonly used as a general anaesthetic agent in the operating theatre and a sedative for critically ill patients including those with COVID-19 in the intensive care unit.

However, we do not know whether propofol worsens or improves COVID-19 by upregulation of ACE2 or by anti-oxidant and anti-inflammatory effects, respectively. As many COVID-19 patients have already been treated in intensive care and undergone surgery under general J o u r n a l P r e -p r o o f anaesthesia, outcomes data are likely to exist. It would be instructive to determine the effects of anaesthetic protocol (general vs regional anaesthesia, total intravenous vs inhalational anaesthesia) and agents on outcomes in COVID-19 patients. Based on the results of such retrospective analyses, further prospective randomised clinical trials (RCTs) could be planned.

Tbc

The anti-inflammatory potential of ACE2/Angiotensin-(1-7)/Mas receptor axis: evidence from basic and clinical research

Propofol increases angiotensin-converting enzyme 2 expression in human pulmonary artery endothelial cells

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Propofol acts at the sigma-1 receptor and inhibits pentazocine-induced c-Fos expression in the mouse posterior cingulate and retrosplenial cortices

Propofol attenuates inflammatory response and apoptosis to protect d-galactosamine/lipopolysaccharide induced acute liver injury via regulating TLR4/NF-κB/NLRP3 pathway